Pre-treatment antinuclear antibody positivity, therapeutic efficacy and persistence of biologics in rheumatoid arthritis (original) (raw)
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis
R. Pellerito, Luca Quartuccio, P. Puttini
Rheumatology, 2009
View PDFchevron_right
Clinical utility of random anti-TNF drug level testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis
M. Bukhari
Arthritis & rheumatology (Hoboken, N.J.), 2015
View PDFchevron_right
FRI0365 Antinuclear Antibodies Induced by Anti-TNF Alpha and its Impact in Clinical Response to Treatment in Rheumatoid Arthritis
M. Bernardes
Annals of the Rheumatic Diseases, 2015
View PDFchevron_right
Brief Report: Association of Rheumatoid Factor and Anti–Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan‐European Registry Analysis
Axel Finckh
Arthritis & Rheumatology, 2016
View PDFchevron_right
The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) α-308 G/G promoter polymorphism
diego catalan
Clinical Rheumatology, 2011
View PDFchevron_right
Clinical parameters and biomarkers for anti-TNF treatment prognosis in rheumatoid arthritis patients
Daniel Bueno
Clinical Rheumatology, 2014
View PDFchevron_right
Predictive Factors of Rituximab Response in Rheumatoid Arthritis: Results From a French University Hospital
S. Mathieu
Arthritis Care & Research, 2013
View PDFchevron_right
Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials
farideh Alasti
Arthritis research & therapy, 2015
View PDFchevron_right
Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study
Heather Litman
The Journal of rheumatology, 2017
View PDFchevron_right
Adjustment in anti-TNF therapy after initial response: long-term follow-up in patients with rheumatoid arthritis
Prodromos Sidiropoulos
2003
View PDFchevron_right
Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis
Y. Braun-moscovici, Erica Hoffer
The Journal of rheumatology, 2006
View PDFchevron_right
Predicting response to anti-TNF treatment in rheumatoid arthritis patients
Marco Antivalle
Autoimmunity Reviews, 2009
View PDFchevron_right
Changes in anti-citrullinated protein antibody titers following treatment with infliximab for rheumatoid arthritis
Mirhelen Mendes de Abreu
The Israel Medical Association journal : IMAJ, 2014
View PDFchevron_right
Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register
Meliha Kapetanovic
Rheumatology, 2007
View PDFchevron_right
Effect of Anti-TNF Antibodies on Clinical Response in Rheumatoid Arthritis Patients: A Meta-Analysis
Peifeng Xian
BioMed Research International
View PDFchevron_right
Anti-TNFα therapy in rheumatoid arthritis and autoimmunity
Domenico Biasi
Rheumatology International, 2004
View PDFchevron_right
Circulating anti-citrullinated peptide antibodies, cytokines and genotype as biomarkers of response to disease-modifying antirheumatic drug therapy in early rheumatoid arthritis
Mahmood Ally, Pieter Meyer, Mohammed Tikly
BMC Musculoskeletal Disorders, 2015
View PDFchevron_right
Antibodies to infliximab and adalimumab in patients with rheumatoid arthritis in clinical remission: a cross-sectional study
Elmo Jensen, Klaus Bendtzen
Arthritis, 2015
View PDFchevron_right
Anti-TNF-α treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients
Ilaria Cavazzana
Clinical and experimental rheumatology
View PDFchevron_right
Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study
Takashi Usui
Arthritis Research & Therapy, 2011
View PDFchevron_right
Comparative effectiveness and predictors of response to tumour necrosis factor inhibitor therapies in rheumatoid arthritis
Ana Rodrigues
Rheumatology, 2012
View PDFchevron_right
Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment
Paul Emery
Rheumatology, 2012
View PDFchevron_right
Serological markers associated with disease activity in patients with rheumatoid arthritis treated with rituximab
Maria Sole Chimenti
Journal of International Medical Research, 2016
View PDFchevron_right
Anti-nucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFα blocking agents in rheumatoid arthritis
Mariangela Manfredi, Maurizio Benucci
Clinical Rheumatology, 2007
View PDFchevron_right
Drug immunogenicity in patients with inflammatory arthritis and secondary failure to tumour necrosis factor inhibitor therapies: the REASON study
Jose Isabel Cisneros Rosas
Rheumatology (Oxford, England), 2018
View PDFchevron_right
Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement
Guido Valesini
Annals of The Rheumatic Diseases, 2004
View PDFchevron_right
Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis
Michael Nurmohamed
Annals of the Rheumatic Diseases, 2009
View PDFchevron_right
Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study
Klaus Bendtzen
PloS one, 2016
View PDFchevron_right